- Philadelphia chromosome-negative myeloproliferative disorders:biology and treatment2007 | First Faculty of Medicine
- Philadelphia chromosome-negative myeloproliferative disorders:biology and treatment2007 | Faculty of Physical Education and Sport
- Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients2018 | Second Faculty of Medicine
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CAMN107AIC05Publication without faculty affiliation
- Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies2018 | Second Faculty of Medicine
- Advances in treatment of Ph-positive adult acute lymphoblastic leukaemia +12008 | Faculty of Medicine in Hradec Králové
- Advances in treatment of Ph-positive adult acute lymphoblastic leukaemia2008 | First Faculty of Medicine
- JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia2005 | First Faculty of Medicine
- JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome- negative CML, and megakaryocytic leukemia2005 | Faculty of Physical Education and Sport
- Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study2012 | Second Faculty of Medicine
- Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party2021 | Publication without faculty affiliation
- Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor2019 | Second Faculty of Medicine
- Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial2018 | Second Faculty of Medicine
- Childhood secondary ALL after ALL treatment2007 | Second Faculty of Medicine, Central Library of Charles University
- Essential thrombocythaemia in children +12008 | Publication without faculty affiliation
- Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans2014 | First Faculty of Medicine, Second Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CAMN107EIC01Publication without faculty affiliation
- Imatinib mesylate efficacy in 72 previously treated Philadelphia-positive chronic myeloid leukemia patients with and without additional chromosomal changes: single-center results +12009 | Publication without faculty affiliation
- Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?2015 | Second Faculty of Medicine
- Role of ruxolitinib in the treatment of primary myelofibrosis2015 | Faculty of Medicine in Hradec Králové
- Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups2020 | Publication without faculty affiliation
- Interlaboratory comparability - an important criterion for selection of a method for relative quntification of BCR-ABL +12009 | Faculty of Medicine in Hradec Králové
- Interlaboratory comparability - an important criterion for selection of a method for relative quntification of BCR-ABL2009 | First Faculty of Medicine
- Analysis of risk factor : the rationale of the guildelines of the Czech Hematological Society for diagnosis and treatment of chronic myeloproliferative disorders with thrombocythemia2006 | First Faculty of Medicine
- Inhibition of AKR1B10-mediated metabolism of daunorubicin as a novel off-target effect for the Bcr-Abl tyrosine kinase inhibitor dasatinib2021 | Faculty of Pharmacy in Hradec Králové
- Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL12019 | Second Faculty of Medicine
